Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax in R/R BCL-2 Positive PTCL
NCT03552692Phase 2Terminated
- Sponsor
- Fondazione Italiana Linfomi
- Start
- Sep 2018
- Primary completion
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of venetoclax in peripheral T-cell lymphoma not otherwise specified (PTCL-NOS), angioimmunoblastic T-cell lymphoma (AITL) and nodal T-follicular helper cell lymphoma (T-FHCL), sponsored by Fondazione Italiana Linfomi. Primary endpoint: Overall Response Rate. Started Sep 2018; status: terminated.
02
Drugs
venetoclax
03
Conditions
peripheral T-cell lymphoma not otherwise specified (PTCL-NOS)angioimmunoblastic T-cell lymphoma (AITL)nodal T-follicular helper cell lymphoma (T-FHCL)
Beyond the preview
Go deeper on NCT03552692.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03552692.